» Articles » PMID: 25802120

Time to Recanalisation in Patients with Cerebral Venous Thrombosis Under Anticoagulation Therapy

Abstract

Background And Purpose: Few studies have investigated the rates of recanalisation after cerebral venous thrombosis (CVT). Our objective was to investigate the recanalisation rate and to identify predictors of recanalisation in patients with CVT.

Methods: We included 102 patients with confirmed first-ever, non-septic CVT. All patients received anticoagulation for 12 months or until complete recanalisation. To assess recanalisation, patients underwent MR venography every 3 months until partial or complete recanalisation or for 12 months after diagnosis. We conducted two parallel analyses of complete recanalisation versus partial and no recanalisation versus any recanalisation. As a secondary objective we explored the influence of recanalisation on outcome and recurrent events. We calculated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysis using a Cox model.

Results: The mean age of patients was 33.5±11 years (80 (78.4%) women). Survival analysis indicated that 50% of the patients had any recanalisation (grades I, II and III) by 64 days and complete recanalisation (grade III) by 169 days. Adjusted Cox proportional model revealed that age <50 years (HR=11.5 95% CI=1.58 to 84.46, p=0.01) and isolated superior sagittal sinus thrombosis (HR=0.39, 95% CI=0.14 to 1.04, p=0.05) predict complete recanalisation, while age <50 years (HR=4.79; 95% CI=1.69 to 13.5, p=0.003) predicts any recanalisation. Patients with complete recanalisation had a greater chance of good functional outcome (HR=5.17; 95% CI=2.8 to 9.53, p<0.001).

Conclusions: We found that recanalisation occurs over time, until month 11. Complete recanalisation may influence functional outcome.

Citing Articles

Anticoagulant Therapy for Cerebral Venous Sinus Thrombosis: A Propensity Score Matching Study and Inverse Probability Weighting.

Liu K, Zhang M, Zhao J, Dai Q, Gao Y, Li S Neurocrit Care. 2025; .

PMID: 40038179 DOI: 10.1007/s12028-025-02225-0.


Functional outcome predictors and recanalization in cerebral venous thrombosis: A single-center cross-sectional study.

Shahid R, Zafar A Turk J Emerg Med. 2024; 24(4):218-225.

PMID: 39564436 PMC: 11573168. DOI: 10.4103/tjem.tjem_65_24.


Safety and Efficacy of Newer Oral Anticoagulants Versus Vitamin K Antagonists in the Management of Cerebral Venous Thrombosis: A Single-Center Ambispective Study from South India.

Ramesh R, Ranganathan L, Raguraman S, Jayakumar K, Rajamanoharan B, Loganathan V Ann Indian Acad Neurol. 2024; 27(4):393-397.

PMID: 38902869 PMC: 11418767. DOI: 10.4103/aian.aian_1096_23.


New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline.

Weimar C, Beyer-Westendorf J, Bohmann F, Hahn G, Halimeh S, Holzhauer S Neurol Res Pract. 2024; 6(1):23.

PMID: 38637841 PMC: 11027218. DOI: 10.1186/s42466-024-00320-9.


Clinicoradiological Features and Long-term Cognitive and Functional Outcome in Patients with Deep Cerebral Venous Thrombosis.

Patwardhan A, Gupta M, Philip M, Rangarajan A, Joshi T, Alladi S Ann Indian Acad Neurol. 2024; 27(1):34-39.

PMID: 38495239 PMC: 10941899. DOI: 10.4103/aian.aian_792_23.